Annals of Surgical Oncology

, Volume 19, Issue 6, pp 1936–1943 | Cite as

Posttherapy Nodal Status, Not Graded Histologic Response, Predicts Survival after Neoadjuvant Chemotherapy for Advanced Gastric Cancer

  • Kazumasa Fujitani
  • Masayuki Mano
  • Motohiro Hirao
  • Yoshinori Kodama
  • Toshimasa Tsujinaka
Gastrointestinal Oncology



Neoadjuvant chemotherapy (NAC) has been attempted as a means of improving survival of potentially resectable advanced gastric cancer (AGC). In the course of exploring the most promising NAC regimen, a superior surrogate marker reflecting overall survival (OS) is necessary. We investigated prognostic factors in AGC patients who underwent NAC followed by gastric resection and evaluated whether histologic response to NAC was predictive of survival.


Seventy consecutive patients with gastric cancer treated with NAC followed by surgical resection between Jan 1, 2000, and Dec 31, 2009, at Osaka National Hospital were identified from a prospective database. Prognostic factors for OS were investigated by univariate and multivariate analyses.


Median survival time for all patients was 668 days after surgical resection. Age less than 65 years (hazard ratio 0.463, 95% confidence interval 0.244–0.879) and pathologic nodal stage of N0–1 (hazard ratio 0.318, 95% confidence interval 0.160–0.635) were identified as significant independent prognostic factors for longer OS, whereas graded histologic response of primary tumor to NAC was statistically significant on univariate analysis, but not on multivariate analysis, as a prognostic factor.


Posttherapy nodal status, not graded histologic response, predicts survival after NAC for AGC and could serve as a reliable surrogate marker for OS in the course of exploring the most promising regimen for NAC.


Overall Survival Median Survival Time Advanced Gastric Cancer Histologic Response Longe Overall Survival 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Conflict of interest

The authors indicated no potential conflicts of interest.


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRefGoogle Scholar
  2. 2.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.PubMedCrossRefGoogle Scholar
  3. 3.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol. 2007;25:Abstr 4510.Google Scholar
  5. 5.
    Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774–80.PubMedCrossRefGoogle Scholar
  6. 6.
    Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23:1237–44.PubMedCrossRefGoogle Scholar
  7. 7.
    Allal AS, Zwahlen D, Brundler MA, et al. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys. 2005;63:1286–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24:3953–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol. 2001;8:123–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Onaitis MW, Noone RB, Fields R, et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol. 2001;8:801–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Ruo L, Tickoo S, Klimstra D, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg. 2002;236:75–81.PubMedCrossRefGoogle Scholar
  14. 14.
    Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347–55.PubMedCrossRefGoogle Scholar
  15. 15.
    Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Gu Y, Swisher SG, Ajani JA, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006;106:1017–25.PubMedCrossRefGoogle Scholar
  17. 17.
    Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229:303–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Brenner B, Shah MA, Karpeh MS, et al. A phase II trial of neoadjuvant cisplatin–fluorouracil followed by postoperative intraperitoneal floxuridine–leucovorin in patients with locally advanced gastric cancer. Ann Oncol. 2006;17:1404–11.PubMedCrossRefGoogle Scholar
  19. 19.
    Mansour JC, Tang L, Shah M, et al. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol. 2007;4:3412–8.CrossRefGoogle Scholar
  20. 20.
    Gaca JG, Petersen RP, Peterson BL, et al. Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. Ann Surg Oncol. 2006;13:340–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer. 1998;1:10–24.PubMedCrossRefGoogle Scholar
  22. 22.
    Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.PubMedCrossRefGoogle Scholar
  23. 23.
    Narahara H, Fujitani K, Takiuchi H, et al. Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology. 2008;74:37–41.PubMedCrossRefGoogle Scholar
  24. 24.
    Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Iwase H, Tsuzuki T, Shimada M, et al. Multicenter phase II study of triple combination with S-1 and cisplatin (CDDP) plus paclitaxel (TXL) in patients with advanced gastric cancer. J Clin Oncol. 2008;26:abstr 4539.Google Scholar
  26. 26.
    Sato Y, Takayama T, Sagawa T, et al. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol. 2010;66:721–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Patel PR, Mansfield PF, Crane CH, et al. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer. 2007;110:989–95.PubMedCrossRefGoogle Scholar
  28. 28.
    Park JW, Kim JH, Choi EK, et al. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011;81:691–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Swanson SJ, Batirel HF, Bueno R, et al. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg. 2001;72:1918–24.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Kazumasa Fujitani
    • 1
  • Masayuki Mano
    • 2
  • Motohiro Hirao
    • 1
  • Yoshinori Kodama
    • 2
  • Toshimasa Tsujinaka
    • 1
  1. 1.Department of SurgeryOsaka National HospitalOsakaJapan
  2. 2.Department of PathologyOsaka National HospitalOsakaJapan

Personalised recommendations